T cell-based targeted immunotherapies for patients with multiple myeloma.
Heidelberg, Germany. In Int J Cancer, May 2015
Besides a comprehensive list of tumor antigens for T cell-based approaches, eight promising antigens, CS1, Dickkopf-1, HM1.24, Human telomerase reverse transcriptase, MAGE-A3, New York Esophageal-1, Receptor of hyaluronic acid mediated motility and Wilms' tumor gene 1, are described in detail to provide a background for potential clinical use.
Development of the First Potent, Selective and CNS penetrant M5 Negative Allosteric Modulator (NAM)
Bethesda, United States. In Unknown Journal, 2014
A recently completed functional, high throughput screen of the Molecular Libraries Probe Production Center's Network (MLPCN) screening deck of ∼360,000 compounds conducted by Scripps Research Institute Molecular Screening Center (SRIMSC) against three of the five muscarinic receptor subtypes (M1, M4 and M5) provided a number of interesting hits.